Nektar Therapeutics Total Liabilities
Nektar Therapeutics total liabilities. Based on the latest financial reports, Nektar Therapeutics (NKTR) has total liabilities worth $192.01 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check NKTR cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Nektar Therapeutics (1994–2025)
Total liabilities of Nektar Therapeutics from 1994 to 2025. This chart illustrates how Nektar Therapeutics's total liabilities have evolved over time, based on quarterly financial data. Explore Nektar Therapeutics long-term investment allocation to see how much of total assets are deployed in long-term investments.
Nektar Therapeutics Competitors by Total Liabilities
The table below lists competitors of Nektar Therapeutics ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Betsson AB
ST:BETS-B
|
Sweden | Skr585.50 Million |
|
Ethos Technologies Inc. Class A Common Stock
NASDAQ:LIFE
|
USA | $219.92 Million |
|
Amprius Technologies Inc.
NYSE:AMPX
|
USA | $23.55 Million |
|
Suzhou Jinhong Gas Co Ltd
SHG:688106
|
China | CN¥4.48 Billion |
|
HIAG Immobilien Holding AG
SW:HIAG
|
Switzerland | CHF911.89 Million |
|
Cofco Biochemical Anhui Co Ltd
SHE:000930
|
China | CN¥7.34 Billion |
|
HBIS Resources Co Ltd
SHE:000923
|
China | CN¥4.35 Billion |
Liability Composition Analysis (1994–2025)
This chart breaks down Nektar Therapeutics's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Nektar Therapeutics (NKTR) total assets.
Liquidity & Leverage Metrics
Nektar Therapeutics Total Liabilities Ratios Explained
Nektar Therapeutics total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.42 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Nektar Therapeutics's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Nektar Therapeutics (1994–2025)
The table below shows the annual total liabilities of Nektar Therapeutics from 1994 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $190.57 Million | -21.61% |
| 2024-12-31 | $243.11 Million | -8.96% |
| 2023-12-31 | $267.05 Million | -22.36% |
| 2022-12-31 | $343.96 Million | -21.41% |
| 2021-12-31 | $437.68 Million | -5.16% |
| 2020-12-31 | $461.47 Million | -19.32% |
| 2019-12-31 | $571.97 Million | +32.22% |
| 2018-12-31 | $432.60 Million | +2.75% |
| 2017-12-31 | $421.04 Million | -12.42% |
| 2016-12-31 | $480.75 Million | -3.00% |
| 2015-12-31 | $495.63 Million | +22.29% |
| 2014-12-31 | $405.29 Million | -22.72% |
| 2013-12-31 | $524.43 Million | +16.34% |
| 2012-12-31 | $450.77 Million | +10.28% |
| 2011-12-31 | $408.74 Million | -5.07% |
| 2010-12-31 | $430.56 Million | -9.00% |
| 2009-12-31 | $473.15 Million | +27.75% |
| 2008-12-31 | $370.38 Million | -27.47% |
| 2007-12-31 | $510.66 Million | -5.63% |
| 2006-12-31 | $541.12 Million | +1.76% |
| 2005-12-31 | $531.74 Million | +91.56% |
| 2004-12-31 | $277.58 Million | -38.67% |
| 2003-12-31 | $452.60 Million | +13.19% |
| 2002-12-31 | $399.87 Million | +0.74% |
| 2001-12-31 | $396.93 Million | +12.87% |
| 2000-12-31 | $351.66 Million | +150.87% |
| 1999-12-31 | $140.18 Million | +653.03% |
| 1998-12-31 | $18.61 Million | -17.88% |
| 1997-12-31 | $22.67 Million | +254.20% |
| 1996-12-31 | $6.40 Million | +113.33% |
| 1995-12-31 | $3.00 Million | +66.67% |
| 1994-12-31 | $1.80 Million | -- |
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosi… Read more